오토인젝터 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Autoinjectors Market size is expected to reach USD 41.49 Billion in 2034 from USD 11.28 Billion (2025) growing at a CAGR of 15.57% during 2026-2034.

The global autoinjectors market has experienced significant growth due to increasing demand for convenient drug delivery systems. Autoinjectors are medical devices designed to administer medications quickly and safely without the need for professional assistance. They are widely used for treating conditions such as allergies, autoimmune diseases, and chronic illnesses. Their ease of use and ability to deliver precise doses have made them increasingly popular among patients.

Key drivers of the autoinjectors market include the rising prevalence of chronic diseases and growing demand for self-administration of medications. Healthcare providers and pharmaceutical companies are focusing on patient-friendly drug delivery systems that improve treatment adherence. Technological advancements in device design, including safety mechanisms and ergonomic features, have also contributed to market expansion.

Looking ahead, the autoinjectors market is expected to grow as healthcare systems emphasize patient convenience and home-based treatment options. Increasing development of biologic drugs and injectable therapies may further boost demand. Innovations in smart drug delivery devices and digital monitoring technologies are also likely to shape the future of this market.

MARKET SEGMENTATION

By Product

• Disposable Auto-Injectors
• Reusable Auto-Injectors

By Indication

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other Therapies

By End Use

• Homecare Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

COMPANIES PROFILED

• Eli Lilly and Company, , SHL Medical AG, AbbVie Inc, Amgen Inc, Owen Mumford Ltd, Ypsomed AG, Teva Pharmaceutical Industries Ltd, Biogen Inc, Mylan NV, Pfizer Inc, Sanofi, Gerresheimer AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOINJECTORS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Disposable Auto-Injectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Reusable Auto-Injectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOINJECTORS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Anaphylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOINJECTORS MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Homecare Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AUTOINJECTORS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Indication
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Indication
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Indication
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Indication
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Indication
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AUTOINJECTORS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 SHL Medical AG
  • 9.2.2 AbbVie Inc
  • 9.2.3 Amgen Inc
  • 9.2.4 Owen Mumford Ltd
  • 9.2.5 Ypsomed AG
  • 9.2.6 Teva Pharmaceutical Industries Ltd
  • 9.2.7 Biogen Inc
  • 9.2.8 Mylan N.V
  • 9.2.9 Pfizer Inc
  • 9.2.10 Sanofi
  • 9.2.11 Gerresheimer AG